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Background: The p38 mitogen-activated protein (MAP) kinase regulates signal 
transduction in response to environmental stress. Pyridinylimidazole compounds 
are specific inhibitors of p38 MAP kinase that block the production of the 
cytokines interleukin-I p and tumor necrosis factor (Y, and they are effective in 
animal models of arthritis, bone resorption and endotoxin shock. These 
compounds have been useful probes for studying the physiological functions of 
the p38-mediated MAP kinase pathway. 
Results: We report the crystal structure of a novel pyridinylimidazole compound 
complexed with p38 MAP kinase, and we demonstrate that this compound 
binds to the same site on the kinase as does ATP. Mutagenesis showed that a 
single residue difference between p38 MAP kinase and other MAP kinases is 
sufficient to confer selectivity among pyridinylimidazole compounds. 
Conclusions: Our results reveal how pyridinylimidazole compounds are potent 
and selective inhibitors of p38 MAP kinase but not other MAP kinases. It should 
now be possible to design other specific inhibitors of activated p38 MAP kinase 
using the structure of the nonphosphorylated enzyme. 
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Introduction 
Mammalian mitogen-activated protein (MAP) kinases are 
serine/threonine protein kinases that mediate intracellular 
signal transduction pathways [1,2]. Members of the MAP 
kinase family share sequence similarity and conserved 
structural domains, and include the extracellular-signal 
regulated kinases (ERKs), Jun N-terminal kinases (JNKs) 
and ~38 kinases. ERKs are activated by mitogen and 
growth factors via a Ras-dependent pathway [3]. In con- 
trast, JNKs and ~38 kinases are activated in response to 
the pro-inflammatory cytokines tumor necrosis factor (Y 
(TNF-a) and interleukin-1 (IL-l), and by cellular stresses 
such as heat shock, hyperosmolarity, ultraviolet radiation, 
lipopolysaccharides (LPS) and inhibitors of protein syn- 
thesis [4-71. Two MAP kinase kinases, MKK3 and MKK6, 
have been identified as p38-specific activating kinases 
that do not phosphorylate JNKs [8-LO], suggesting that 
the activation of ~38 MAP kinase is mediated by a distinct 
but parallel signaling pathway(s) to that of JNKs. 
The first ~38 MAP kinase (also termed p38/p40/RK/SAPK/ 
CSBP) was cloned following its identification as a kinase 
that was tyrosine-phosphorylated after stimulation of mono- 
cytes by LPS [5]. The ~38 MAP kinase was later identified 
as the drug target for a group of pyridinylimidazole com- 
pounds that block the production of IL-1B and TNF-o( 
from monocytes stimulated by LPS [ll]. SB-203580, a 
2,4,5-triarylimidazole (Figure 1; Z), is a potent ~38 MAP 
kinase inhibitor that is highly selective relative to other 
kinases, including other closely related MAP kinases 
[l&13]. SB-203580 has been shown to be effective in 
animal models of arthritis, bone resorption and endotoxin 
shock [14], and has proven to be a useful research tool in 
determining the role of the p38-mediated kinase pathway 
17,151. But, as yet, no structural studies have been reported 
that describe the binding and p38-selectivity of this class 
of compound. 
The ~38 MAP kinase has been implicated in the transla- 
tional control of cytokine gene expression [16]. In addi- 
tion, it phosphorylates and activates transcription factors 
ATF-2, Elk-l, CHOP-l, and MEFZC [10,17-181, indicat- 
ing the involvement of ~38 MAP kinase in transcriptional 
regulation. The ~38 kinase has also been implicated in the 
activation of MAP-kinase-activated protein kinases (MAP- 
KAPKs) 2 and 3 [19-201, activation of platelets [15], pro- 
duction of IL-6 and IL-8 [7], induction of cyclooxygenase 
2 [Zl], and apoptosis of neuronal cells [ZZ]. Selective mod- 
ulation of ~38 MAP kinase activity could therefore pro- 
vide therapeutic intervention for disorders ranging from 
inflammatory diseases to neurodegenerative diseases. 
The crystal structure of apo-, unphosphorylated ~38 MAP 
kinase has been described [23-241. The amino acid 
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Selected pyridinylimidazole compounds. (1) VK-1991 1 : 4-(4-fluoro- 
phenyl)-l-(4-piperidinyl)-5-(4-pyridyl)-imida.zole. (2) SB-203580: a 
2,4,5-triarylimidazole. (3) An Nl -morpholinopropyl-4,5-diarylimidazole 
derivative. (4) SB-202190: a 2,4,5-triarylimidazole. 
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Determination of dissociation constant K, for VK-1991 1 with 
nonactivated and activated p38 MAP kinase. Both activated (filled 
circles) and nonactivated (open squares) p38 MAP kinase have similar 
affinities for VK-19911 (Kd = 12 + 1 nM and 15 rt: 5 nM, respectively). 
The concentration of p38 MAP kinase (activated or nonactivated) was 
maintained at 80 nM in 0.1 M HEPES buffer, pH 7.6, containing 10 mM 
magnesium chloride and 25 mM P-glycerophosphate. VK-19911 in 
DMSO (10 p,M) was added in small aliquots. The excitation and 
emission wavelengths were 280 nm and 375 nm, respectively. Under 
the experimental conditions, DMSO did not have any significant effect 
on the emission signal. The emission intensities for the activated p38 
MAP kinase shown in this figure were scaled down twofold from the 
original. The titration curves were fitted to Equation 1 (see the 
Materials and methods section) to obtain the dissociation constants. 
sequences of ~38 and ERK2 are 48% identical and their 
folds and topology are similar [23-251. Enzymes in the 
MAP kinase family as a whole are characterized by two 
domains separated by a deep channel in which substrates 
have the potential to bind. The amino-terminal domain 
creates a binding pocket for the adenine ring of ATP, and 
the carboxy-terminal domain contains the presumed cat- 
alytic base, magnesium-binding sites, and phosphorylation 
lip (Thr-X-Tyr motif; see later). Here, we report the 
crystal structure of p38 MAP kinase bound to VK-19911 
- 4-(4-fluorophenyl)-1-(4-piperidinyl)-5-(4-pyridyl)-imida- 
zole; Figure 1; 1 - an inhibitor from the pyridinylimida- 
zole class of compounds. X-ray diffraction data, in concert 
with mutagenesis results, reveal for the first time the 
enzyme conformational changes and amino acid contacts 
responsible for the selective and potent binding of the 
pyridinylimidazole compounds within the ATP-binding 
site of p38 MAP kinase. 
Results and discussion 
The p38 MAP kinase-inhibitor complex 
VK-19911 (Figure 1; 1) is a potent ligand for both nonphos- 
phorylated and phosphorylated ~38 MAP kinase, having 
similar dissociation constants with each form of the 
enzyme (K,=lSnM and 12nM, respectively, as measured 
by fluorescence emission at 375 nm upon binding VK-19911 
to the enzyme; Figure 2). We report the structure of non- 
phosphorylated ~38 MAP kinase bound to VK-19911 at 
2.6A resolution as determined by X-ray diffraction. 
Electron density for the mainchain atoms of p38 MAP 
kinase complexed with the inhibitor VK-19911 is visible 
for residues 5-352, with breaks at residues 14-15, 118-122, 
and 170-174 (data not shown). Four residues at the amino- 
terminus of ~38 MAP kinase, and six amino acids remain- 
ing from the thrombin cleavage site (see [23]), are not 
visible in the electron density map. The presence of these 
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Figure 3 
Pyridinylimidazole compounds bind in the 
ATP-binding site. Stereo CCX representations 
of the structures of p38 MAP kinase (gold) 
complexed with VK-19911 (red liquorice 
bonds) and ERK2 (dark blue) complexed with 
ATP (light blue liquorice bonds) are shown 
after superposition of their amino-terminal 
domains. The phosphorylation lip of p38 MAP 
kinase is highlighted with orange liquorice 
bonds. The sidechains of Thrl60 and Tyr182 
that become phosphorylated upon activation 
of p38 MAP kinase are shown. A thin dotted 
line connects Phel69 to Asp1 74 and may 
trace approximately the path of the disordered 
residues between these two amino acids. The 
distance between either Thrl80 or Tyr182 
and VK-19911 is 24 A. Because the residues 
in the phosphorylation lip are quite distant 
from the ligand-binding site, it is expected 
from the structure that the activation of p38 
MAP kinase should have little effect on the 
shape of the binding pocket and hence the 
affinity of p38 MAP kinase for compounds in 
the pyridinylimidazole class. 
amino acids in the crystal structure has been confirmed by 
sequence analysis. Seven residues at the carboxyl terminus 
are also disordered. The phosphate anchor, which contains 
the consensus sequence Gly-X-Gly-X-X-Gly (residues 
31-36 in ~38 MAP kinase; data not shown), is highly 
mobile and these residues are also omitted from the model. 
The inhibitor binds in the ATP-binding site 
A comparison of the structures of the ~38 MAP kinase-VK- 
19911 complex and the ERKZ-ATP complex suggests that 
VK-19911 competes with ATP for binding at the active site 
(Figure 3). In the structure of the ERKZ-ATP complex, 
the amide nitrogen of Met106 forms a hydrogen bond with 
the Nl nitrogen of the adenine ring of ATP (Figure 4a), 
whereas the corresponding residue in ~38 MAP kinase, 
Met109, forms a hydrogen bond with N4 of the pyridine 
ring of VK-19911 (Figure 4b). In addition to the common 
hydrogen bond, the two ligands have comparable van der 
Waals contacts with surrounding residues in each complex, 
for example, amino acid sidechains in the ERKZ structure 
that make contact with ATP include Va137, AlaSO, Gln103, 
Met106, and Asp165. In comparison, the equivalent 
residues in p38 MAP kinase, which include Va138, Ala.51, 
ThrlOh, Met109 and Asp168, interact with at least a 
portion of VK-19911. These data suggest that VK-19911 is 
competitive with ATP in the ATP-binding pocket of p38 
MAP kinase. In fact, enzymic analysis confirms that 
VK-19911 is competitive with ATP as an inhibitor of p38 
MAP kinase (S.P., unpublished observations). 
Enzyme-inhibitor interactions 
We examined the conformational preferences of VK-19911 
to determine the strain energy of its bound state. Our 
calculations indicate that the global energy-minimum 
structure for VK-19911 is similar to the crystallographically 
observed bound conformation. These findings help explain 
the high potency of VK-19911, because the molecule binds 
in the active site of ~38 MAP kinase in a very low-energy 
conformation. 
Many of the contacts between VK-19911 and ~38 MAP 
kinase arise from the para-fluorophenyl ring, which is 
completely shielded from solvent and is within favorable 
van der Waals distance of the carbon atoms of ten hydro- 
phobic residues (Va138, AlaSl, Va1.52, Lys53, Leu7.5, Ile84, 
Leu86, Leul04, Va1105 and ThrlO6; Figure 4b). This 
ring, which is a common substituent in many of the most 
potent pyridinylimidazole inhibitors reported [26], con- 
tributes significantly to the affinity of VK-19911 to p38 
MAP kinase by burying -18OA2 of the enzyme’s surface 
area upon binding. 
Two hydrogen bonds are formed between VK-19911 and 
~38 MAP kinase. The pyridine ring nitrogen accepts a 
proton from the backbone amide nitrogen of Met109, and 
the nitrogen of the piperidine ring forms a salt bridge with 
the sidechain carboxylate group of Asp168 (Figure4b). 
Based on observations of the distance and geometry, it 
appears that N4 in both the pyridine and piperidine rings 
affords the best electrostatic interaction with ~38 MAP 
kinase. Additional enzyme-ligand interactions include 
contacts between the pyridine ring and Ala51, Thr106, 
and His107, while the piperidine moiety interacts with 
Met109 and Leu167. The imidazole ring, which contacts 
only Lys53 and Asp168, appears to assist in the binding by 
positioning the piperidinyl and aryl rings. 
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Figure 4 
Illustrations of the active sites of ERK2 and 
p38 MAP kinase. (a) Stereo drawing of the 
active site of ERK2. The refined model of the 
ERKP-ATP complex in the region of the ATP- 
binding site is shown. Some of the sidechains 
in contact with ATP (see text) are identified 
(one-letter code and sequence position). 
Atoms in the figure are colored: carbon, 
yellow; nitrogen, blue; oxygen, red; and sulfur, 
yellow. ATP is displayed by liquorice bonds, 
Hydrogen bonds between ATP and ERKP are 
highlighted by dashed lines. The distance 
between the amide-nitrogen ofOMetl 06 and 
Nl of the adenine ring is 3.17A, and the 
distance between the ATP adenine-ring amino 
group and the carbonyl oxygen of Asp1 04 is 
3.01 A. Water molecules in the vicinity of the 
ligand, and residues 30-34 of the phosphate 
anchor, were omitted for clarity. (b) Stereo 
drawing of the active site of p38 MAP kinase. 
The refined model of the complex in the region 
of the VK-1991 1 -binding site is shown. Some 
of the sidechains in contact with the inhibitor 
(see text) are identified (one-letter code and 
sequence position). Atoms in the figure are 
colored: as in (a) and fluorine, green. The 
inhibitor is displayed in liquorice bonds. The 
view is approximately the same as in (a). 
Hydrogen bonds between the inhibitor and 
p38 MAP kinase are highlighted by dashed 
lines. The distance between the amide- 
nitrogen of Met1 09 and N4 of the pyridine 
ring is 2.98A, and the distance between N4 
of the piperidine ring and the sidechain 
carboxylate oxygen of Asp1 68 is 2.85A. 
Water molecules in the vicinity of the ligand 
were omitted for clarity. Residues of p38 MAP 
kinase that have at least one atom within 4A 
of any atom in the inhibitor are: Val38, Ala51, 
Lys53, lle84, Leu75, Leu86, LeulO4, Val105, 
Thr106, His1 07, Leu108, Met1 09, Leul68, 
and Asp1 69. As in (a), the pyridine nitrogen 
must reside at position 4 for optimal 
interaction with the Met1 09 amide nitrogen, 
while simultaneously permitting the 
4-fluorophenyl ring to make many van der 
Waals contacts. (c) Changes in the p38 MAP 
kinase active site upon ligand binding. The 
structure of the apo-, nonphosphorylated form 
of p38 MAP kinase (blue) is compared with 
the refined structure of the VK-1991 1 
inhibited complex (gold). The amino acids, 
listed in (b), with at least one atom within 4A 
of the inhibitor were used to superimpose the 
two’stru’ctures. The root mean square (rms) 
deviation of these 14 residues is 0.42A2. The 
inhibitor is colored red and displayed in 
liquorice bonds. Liquorice bonds are also 
used to highlight the shift of Met1 09 (lower 
left), and the rotation about x, of Thr106 
(center). The water molecule bound in the 
apo-structure that is displaced by the 
y-hydroxyl group of Thr106 upon ligand 
binding is highlighted as a light blue sphere. 
Residues 30-36 were omitted from the figure 
for clarity. Larger sidechains at position 106, 
like glutamate in ERKP and methionine in JNK 
and p38ylSAPK3, would block VK-I 9911 
binding by occupying the space filled by the 
para-fluorophenyl ring. 
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Both global and local conformational changes of ~38 MAP 
kinase accompany binding of VK-19911. The most signifi- 
cant movement occurs at Met109 such that C, shifts 7.7A 
from its location in the apo-structure (Figure 4c) to contact 
the piperidine ring of VK-19911. The conformational 
change of the methionine sidechain, which is positioned at 
the interface between the two domains of ~38 MAP kinase 
(Figure 3) may be linked to a global change in the structure 
that occurs upon VK-19911 binding. When equivalent 
residues from the carboxy-terminal domain (amino acids 
110-117, 123-169 and 175-318) of the apo-structure and 
the VK-19911-bound structure are superimposed, residues 
5-60 of the amino-terminal domain are shifted by an 0 
average of 1.5A. Most shifts in the structure of the complex 
occur towards VK-19911 or towards the space vacated by 
the Met109 sidechain (not shown). In contrast, residues of 
the amino-terminal domain that are more distant from the 
compound and Met109 maintain their position. Thr106 
also undergoes a conformational change in response to the 
binding of VK-19911, rotating 120” about x,. This move- 
ment changes the location of the ThrlO6 y-hydroxyl group, 
which then forms a hydrogen bond with the carbonyl 
oxygen of Gly85 in the VK-19911-bound complex. In the 
apo-structure, the hydrogen bond to the carbonyl oxygen of 
Gly85 is formed with a water molecule, which is displaced 
in the inhibitor complex (Figure 4~). The 120” rotation also 
places the Thr106 y-methyl group in favorable van der 
Waals contact with thepara-fluorophenyl ring of VK-19911. 
Inhibitor selectivity 
Members of the MAP kinase family share conserved struc- 
tural domains and a high degree of sequence similarity, par- 
ticularly in the ATP-binding site. Not surprisingly, a 
number of ~38 MAP kinase residues that make contact 
with the inhibitor are conserved among other MAP kinases. 
Thr106 is an exception, however, and is replaced by 
methionine in p38y/SAPK3 (a newly discovered ~38 
homolog) [27,28] and the JNK kinases, and by glutamine in 
the ERKl and ERKZ kinases. Analysis of the crystal struc- 
ture suggested that substitution of ThrlO6 with methionine 
or glutamine would interfere with binding of pyridinylimi- 
dazole inhibitors by blocking access to the pocket which 
accepts the fluorophenyl ring. Thus, the residue corre- 
sponding to ThrlO6 in other MAP kinases may be a critical 
determinant for specificity of these compounds. 
To test this hypothesis, we used site-directed mutagene- 
sis to change ThrlO6 in ~38 MAP kinase to methionine or 
alanine. Neither mutation affected the overall activity of 
the kinase nor its degree of activation in vitro by MKK6 
(data not shown). Substitution of ThrlO6 with methion- 
ine, however, rendered the enzyme resistant to VK-19911 
at a level similar to that seen for p38ylSAPK3 (Figure 5a). 
Furthermore, the ThrlOb+Met mutant was also resis- 
tant to inhibition by the 2,4,5triarylimidazole SB-202190 
(Figure 5b), indicating that these structurally similar 
inhibitors are likely to bind in a similar manner. Based on 
the structure of ~38 MAP kinase complexed with the 
inhibitor, replacing ThrlO6 with alanine would be expected 
to have little effect on inhibitor binding because the 
sidechain of alanine should not interfere with the position- 
ing of the fluorophenyl ring. As predicted, the ~38 MAP 
kinase ThrlOb-+Ala mutant is as sensitive to VK-19911 
or SB-202190 as the wild-type enzyme (Figure 5). These 
results demonstrate that ThrlO6 is critical for binding pyri- 
dinylimidazole compounds selectively to ~38 MAP kinase, 
and that the presence of larger sidechains at the corre- 
sponding residue may explain the resistance of other MAP 
kinase homologs to these inhibitors. 
Activation of p38 MAP kinase is unlikely to change its 
affinity for pyridinylimidazole compounds 
MAP kinases reach maximum enzymic activity [29] only 
after phosphorylation by specific MAP kinase kinases 
within a Thr-X-Tyr motif, where X is Pro, Glu, or Gly for 
ERK, JNK, or ~38 MAP kinase, respectively [l-Z]. Because 
the Thr-X-Tyr motif is located in a surface loop near the 
active site, this region of the enzyme is often referred to as 
the phosphorylation lip or activation segment. The crystal 
structure of the apo-, nonphosphorylated ~38 MAP kinase 
enzyme indicates that its phosphorylation lip includes 
residues 170-178, which occupy the peptide-binding 
channel, and residues 179-185, which include the two 
phosphorylation sites Thr180 and Tyr182 1301 (Figure 3). 
Upon phosphorylation at Thr180 and Tyr182, it is thought 
that a conformational change in the phosphorylation lip 
occurs that could influence the binding of pyridinylimida- 
zole compounds. But the binding affinity of VK-19911 for 
activated ~38 MAP kinase is similar to that of the nonphos- 
phorylated enzyme (K, = 12 nM and 15 nM, respectively; 
Figure 2). Inspection of the structure of the VK-19911 
complex shows that the closest distance between the 
pyridinylimidazole compound and any residue in the phos- 
phorylation lip is -lOA, and that residues Thr180 and 
Tyr182 are -24A removed from the imidazole ring of the 
inhibitor (Figure 3). The large distance between the 
inhibitor-binding site and the phosphorylation lip reduces 
the likelihood that the activation of ~38 MAP kinase will 
have a large effect on the binding affinity of VK-19911 or 
other pyridinylimidazole compounds. 
Structure-activity relationship for pyridinylimidazole 
inhibitors 
The complex of VK-19911 (Figure 1; 1) bound to ~38 MAP 
kinase provides an opportunity to rationalize published ~38 
MAP kinase inhibition data for other pyridinylimidazole 
compounds, such as the 2,4,5-triarylimidazole derivative 
(Figure 1; 2) [31] and the Nl-morpholinopropyl-4,5diaryl- 
imidazole derivative (Figure 1; 3) (321. 
Figure 6 summarizes the binding features found for 
VK-19911. The imidazole ring of VK-19911 appears to 
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Figure 5 Figure 6 
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Inhibition of p38 MAP kinase, p38ylSAPK3 and p38 MAP kinase mutants 
by (a) VK-19911 and (b) SB-202190. Kinase activity was measured as 
described in the Materials and methods section using myelin basic 
protein as a substrate, in the absence or presence of inhibitors at the 
concentrations shown. Kinase activity is expressed relative to the activity 
measured in the absence of inhibitor (set to 100%). 
serve mainly as a scaffold for positioning the piperidinyl 
and aryl rings in place. Other studies, however, have 
implicated N3 in the imidazole ring as a critical determi- 
nant for the binding of pyridinylimidazole inhibitors to 
~38 MAP kinase [26]. The proximity of N3 to the posi- 
tively charged sidechain of Lys53 suggests that a nitrogen 
bearing a lone pair of electrons may be required in this 
Hydrophobic 
(Lys53, Leu75, Leu86, 
LeulO4. ThrlO6) 
Salt bridge 
(Asp1 68) 
Two-dimensional schematic drawing of VK-19911 binding to p38 
MAP kinase. 
position to avoid a repulsive interaction, rather than to 
form a favorable interaction with ~38 MAP kinase. Alter- 
natively, the Lys53 sidechain may interact dynamically 
with the N3 lone pair either directly or through solvent. 
The pyridyl ring of VK-19911 forms a hydrogen bond with 
the backbone carbonyl of Met109. The orientation of the 
4-pyridyl ring with respect to the enzyme suggests that the 
3-pyridyl and Z-pyridyl derivatives should be unable to 
effectively participate in this hydrogen bond and should 
therefore be substantially less active. In addition, replacing 
the pyridyl ring with a phenyl ring should reduce activity as 
a result of the loss of hydrogen bonding and the introduc- 
tion of steric clashing. These observations are in accord 
with literature results [26] for compounds related to 2 and 3. 
The fluorophenyl ring of VK-19911 is buried in a 
hydrophobic cleft, leaving minimal space for additional 
substituents to the ring. The OC%O and meta positions on 
one face of the fluorophenyl ring are sterically blocked by 
the backbone carbonyl of Ala51 and the sidechain of Va138, 
respectively, while the para position, as well as the o&o 
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and meta positions, of the opposing face of the ring appear 
to allow small substituents. This is consistent with litera- 
ture data which show that 3,Sdisubstitutions reduced the 
potency, whereas monosubstitution at the meta or para 
position increased potency of inhibitors in this class [26]. 
The piperidinyl ring of VK-19911 has two components of 
binding: hydrophobic overlap with the sidechains of 
Met109 and Leu167, and a salt bridge with Asp168. Inter- 
actions of C3 and C5 of the piperidin-4-yl ring with the 
oxygens of Asp168 are slightly repulsive. Replacement of 
the piperidin-4-yl moiety with 3-carboxypropyl would 
place the carboxyl group in direct proximity to the Asp168 
sidechain, accounting for the severe loss of binding affinity 
of this compound [26]. 
Significance 
We have determined the structure of p38 mitogen-acti- 
vated protein (MAP) kinase bound to an inhibitor - 
4 - (4 -fluorophenyl)- l- (4-piperidinyl) - 5 -( 4-pyridyl)-imida- 
zole; VK-19911 - from the pyridinylimidazole class of 
compounds. We found that both global and local confor- 
mational changes accompany the binding of VK-19911. 
By comparing the structure of the p38 MAP kinase-VK- 
19911 complex with that of the complex formed by the 
extracellular-signal regulated (ERK) kinases and ATP, 
it is clear that VK-19911 inhibits the p38 MAP kinase 
activity by blocking access of ATP to the active site. Our 
structural and mutagenesis data established that a single 
amino acid difference at residue 106 between p38 MAP 
kinase and other MAP kinases is sufficient to confer 
selectivity for VK-19911. It is thought that both the Nl- 
substituted 4,.5-diarylpyridinylimidazoles and the 2,4,5,- 
triarylimidazoles bind to p38 MAP kinase in a similar 
manner, and that all compounds in these classes inhibit 
p38 MAP kinase by competing with ATP. Furthermore, 
activation of the enzyme does not have a significant 
impact on the binding affinity for VK-19911, indicating 
that the shape of the inhibitor-binding pocket is unlikely 
to change upon phosphorylation of p38 MAP kinase. It 
is anticipated that the structure of p38 MAP kinase com- 
plexed with VK-19911 should aid the design of other 
highly specific inhibitors of this enzyme. 
Materials and methods 
Synthesis of VK-19911 
The key step in the synthesis of VK-19911 uses a 1,3 dipolar cycload- 
dition [32,33-341 between the anion of 4-fluorophenyltolythiomethyl- 
isocyanide (Figure 1; 3) [32,34] and the imine (Figure 7; 6). Thus, 6 
was prepared in one step from Boc-piperidine (Figure 7; 5) [35] and 
pyridine-4-carboxaldehyde. The anion of 4-fluorophenyltolythiomethyl- 
isocyanide was generated by treatment with 1,5,7+riazabicylco- 
[4.4.0]dec-5-ene (TBD) and then condensation with imine 6 to form the 
Boc-protected imidazole 7 (Figure 7). Deprotection of the Boc group 
with 4 N HCI in dioxane afforded the desired final product. 
Crystallization of p38 kinase and structure determination of 
VK- 199 11 complex 
Sample preparation for crystallization of p38 MAP kinase has been pub- 
lished [23]. Crystals of nonphosphorylated, apo-p38 were grown by 
vapor diffusion as described [23]. A single crystal 0.35mmx0.25mmx 
0.03 mm in .size was equilibrated slowly over 48 h in a buffer of 50 mM 
sodium HEPES, pH 7.5, 0.7 M sodium citrate, 144mM (NH,),SO,, 5 mM 
VK-1991 1, and 17.5% glycerol in preparation for X-ray data collection 
at -169°C.’ 
X-ray data were collected on an Raxis IIC image plate and processed 
and scaled using DENZO and SCALEPACK [36]. The crystals had 
space group symmetry P2,2*2,, with unit cell dimensions a=45.36& 
b=86.09& and c=l25.92A. The crystal exposed to the compound 
showed a 2.OA increase in cell dimension along the c-direction with 
respect to ape-crystals. R-merge for the data was 6.20/o, with I/sig(l) = 
6.0 at 2.6A resolution. R-merge in the highest resolution shell was 
14.9%. The X-ray data comprised 13,827 unique reflections with IFI> 
a(F) derived from 42,304 intensity measurements. The data were 87% 
complete overall and 81 O/o complete in the 2.72-2.60 /! resolution shell. 
X-ray coordinates of apo-, nonphosphorylated p38 kinase [23] were 
used as a starting model for refinement of the inhibited complex (PDB 
accession number 1 WFC). All thermal factors were set to 1 0.0A2. The 
R-factor0 after rigid body refinement was 31% for data between 
lo-3.OA. The resolution of the maps and model was gradually 
increased to 2.6A resolution by cycles of model building, positional 
refinement, and thermal factor refinement, interspersed with torsional 
dynamics runs. All stages of model refinement were carried out using 
the XPLOR suite of programs [37]. Our current p38 model in complex 
with VK-19911 contains 333 protein residues, 102 water molecules, 
and one inhibitor molecule, and has an R-factor of 21.8% versus all 
data with IFl>o(F) between 8-2.6a resolution (13,336 reflections). 
PROCHECK and XPLOR were used to analyze the model stereochem- 
istry. 90% of the p38 residues were located in the most favored region 
of the phi-psi plot, and 9% in the additional allowed regions. The model 
had deviations from ideal bond lengths and angles of 0.01 1 /! and 2.8”, 
respectively, and all other indications of stereochemistry were average 
or better then average for a structure determined at 2.6A resolution. 
No electron density was observed for ~38 amino acids l-4, 14-l 5, 
118-l 22, 170-l 74, and 353-359 in the complex and these residues 
were not, therefore, included in the model. Residues Argl 0, Argl49, 
His199 and Leu353 were modeled as alanine because the electron 
density for these sidechains was poor. 
Expression and purification of kinases 
EST clones containing the entire coding regions of human MKK6 
(MKKGb) [9] (GenBank accession number R15387) and p38ylSAPK3 
[26-271 (GenBank accession number H14292) were obtained from 
Research Genetics. p38 kinase, p38y and a constitutively active 
mutant of MKK6 (MKKG S207D, T211 D) were expressed as amino-ter- 
minal His-tagged proteins in Escherichia co/i and purified by nickel- 
chelate chromatography using standard protocols (Qiagen). Single 
amino ac,id substitutions by alanine or methionine at residue 106 were 
introduced into p38 by oligonucleotide-directed mutagenesis. 
Activation and assay of p38 kinases 
For activation, ~38, p38y or p38 mutants (500nM) were incubated 
with MKK6 (25 nM) for 30 min at 30°C in a mixture containing 1 mM 
ATP, 1 mM MgCI,, 1 mM MnCI,, 25mM HEPES pH7.5, and 0.1 mM 
DTT. After activation, ~38 kinases were diluted into kinase reaction mix 
to give the following final concentrations: 100 nM ~38, 5 nM MKKG, 
200 mM ATP, 8 mM 33P-ATP, 5 mM myelin basic protein, 1 mM MgCI,, 
1 mM MnCI,, 25mM HEPES, pH 7.5, and 0.1 mM DTT. Inhibitors were 
added to the kinase reaction mix before the addition of ~38. After 
incubation at 3O’C for 15-30 min, the reactions were terminated by 
spotting onto phosphocellulose paper squares which were washed 
extensively with phosphoric acid, dried, and counted. 
Dissociation constant for VK-19911 
The fluorescence measurements were obtained on Perkin-Elmer LS 
50B fluorimeter. Excitation of ~38 (activated or nonactivated) at 280 nm 
results in emission at 335 nm. Upon VK-19911 binding to ~38, a new 
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Figure 7 
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Synthesis of VK-19911. Reagents and 
conditions: (i) pyridine-4carboxaldehyde, 
MgSO,, toluene, 18 h, room temperature; (ii) 
4-fluorophenyltolythiomethylisocyanide, 
1,5,7-triazabicyclo[4.4.0Idec-5-ene (TBD), 
methylene chloride; (iii) 4 N HClldioxane, 1 h. 
emission band appears, centered at 375nm, with a concomitant 
decrease in emission at 335nm. A cuvette of 1 cm path length was 
placed in the cell compartment with 1.5 ml of 0.1 M HEPES buffer, 
pH 7.6, containing 10 mM magnesium chloride, 25 mM @glycerolphos- 
phate and 80nM p38 (activated or nonactivated). The contents of the 
cuvette were stirred continuously by the magnetic stirrer in the cell 
compartment. The excitation and emission wavelengths were set at 
280nm and 375nm, respectively. A DMSO solution of VK-1991 1 at 
lOp,M was added 1 )*I at a time without removing the cuvette. The 
signal at 375nm was noted as a function of the concentration of VK- 
1991 1. The data were fitted to Equation 1 to evaluate the dissociation 
constant, K,, for VK-19911. 
F=0.5*EXT"((Kd+Lo+EO)-((K~+Lo+EO)2-4"EO*LO)1~2) (1) 
where F is the observed fluorescence, EXT is the molar fluorescence 
coefficient, L, is VK-1991 1 concentration, and E, is p38 MAP kinase 
concentration. 
Analysis of the bound conformation of VK- 199 11 
To determine the strain energy of the bound state we examined the 
conformational preferences of VK-19911. The piperidine ring can flip 
into two distinct chair conformations. In addition, the piperidine, 
benzene, and pyridine rings all can rotate. Ab inifio calculations at the 
Hartree-Fock 6-31 G* level were carried out for a series of low-energy 
conformations using Gaussian-94. First, we determined that the imida- 
zole ring has a 3 kcal/mol preference to adopt an equatorial arrange- 
ment with respect to the piperidine ring. Such a strong equatorial 
preference was expected based on the known 3 kcal/mol preference 
for equatorial phenylcyclohexane [38]. Next we studied the rotational 
preferences of the piperidine, pyridine, and benzene rings with respect 
to the imidazole. All three rotors are fairly ‘soft’, allowing rotations of 
f30’ with little energetic penalty. Our calculations reveal that the 
global energy minimum structure for VK-1991 1 is similar to the crystal- 
lographically observed bound conformation. Furthermore, the calcu- 
lated energy of the X-ray conformation was only - 1.5 kcal/mol above 
the global minimum. 
Note added in proof 
The crystal structure of human p38 MAP kinase in complex with a 
2,4,5-triarylimidazole analog of SB-203580 at 2.OA resolution was 
published recently (Tong, L., et al., & Pargellis, CA. (1997). A highly 
specific inhibitor of human p38 MAP kinase binds in the ATP pocket. 
Nat Sfruct EGO/. 4, 31 l-316). 
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